Novartis said that Coartem dispersible contains the same amounts of artemether and lumefantrine as Coartem, the leading artemisinin-based combination therapy (ACT) in Africa, and is the first dispersible
The trial is a proof-of-concept, open-label study with pediatric subjects randomized according to weight group and titrated to receive one of four doses over a six-week treatment period.
The results showed that Embeda provided continued pain relief for up to 12 months in opioid-tolerant patients with chronic, moderate to severe, non-malignant pain. Findings also showed that
The company has posted net sales of $10.08 billion for the fourth quarter of 2008, an increase of 1%, compared to $9.93 billion reported for the fourth quarter
The FDA approval is based on enhancements made by OraSure to the manufacturing process and product packaging of its OraQuick Advance test, and represents a six-month increase in
Together with the hepatitis C virus (HCV) Respond-2 study, a pivotal Phase III study in patients who failed prior treatment that completed enrollment in November 2008, the company
In addition, there will be the elimination of approximately 410 CSO sales representative positions. In total, Sepracor sales positions will be reduced to approximately 1,325. These reductions, together
Excluding restructuring charges in both fiscal 2008 and 2009, third quarter fiscal 2009 adjusted operating income was $25 million, up 20%, and adjusted earnings per share were $0.63,
He earlier served as the president and chief executive officer (CEO) of Jostens, Inc., from 1994 to 2004 and as chairman from 1998 to 2004. Before joining Jostens,
The terms of the agreement includes an upfront payment, regulatory milestones and sales milestones. The total value of the upfront payment and milestones are $4.75 million. In addition,
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.